Study to Assess Tezampanel for Opioid Withdrawal Syndrome
Phase 1
40
about 1.1 years
18–65
1 site in IN
About this study
This trial is testing whether Tezampanel (TZP) can help with opioid withdrawal syndrome in people who have opioid use disorder. Participants will receive either TZP or a placebo daily for 7 days during their stay at the research center.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Tezampanel
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: To evaluate systemic tolerability and safety of intravenous tezampanel administration.
Secondary: To characterize Area Under the Curve (AUC) concentration of tezampanel, To characterize Cmax (maximum concentration) of tezampanel
Psychiatry / Mental Health